Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Inclusion Criteria: * ≥18 years old * Positive PCR test for SARS-CoV-2 within 5 days of admission to hospital * Normoxic (not receiving supplemental oxygen) * Able to provide informed written consent (or, if patient is unable, have substitute decision maker available) Exclusion Criteria: * Absolute contraindications to Paxlovid or Veklury (any of the following): Severe allergy to Paxlovid or Veklury (e.g. anaphylaxis), co-administration with drugs highly dependent on CYP3A for clearance, co-administration with potent CYP3A inducers * Exposure to Paxlovid or Veklury within previous 14 days; * Receiving supplemental oxygen; * Known positive SARS-CoV-2 PCR or rapid antigen test 5-90 days prior to admission; * Limited life expectancy estimated to be ≤3 months; * Pregnant and breastfeeding women